STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

News

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Arcutis Biotherapeutics reported total revenues of $38.1 million in Q3 2023, with net product revenues for ZORYVE cream reaching $8.1 million, a 70% increase compared to Q2 2023. The company received FDA approval for the expanded indication of ZORYVE in plaque psoriasis for children down to the age of 6. Arcutis also made progress in its atopic dermatitis program with the submission of a supplemental New Drug Application and positive trial results. The company appointed new executives and strengthened its balance sheet with a $100 million follow-on offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
earnings
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. has granted 52,500 restricted stock units of its common stock to eight newly hired employees. The awards were approved by the Compensation Committee and granted under the 2022 Inducement Plan. The restricted stock units vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
none
-
News

Arcutis to Report Third Quarter 2023 Financial Results

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. will host a conference call and webcast on November 3, 2023, to report its third quarter financial results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences earnings
News

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

Rhea-AI Summary
Arcutis Biotherapeutics announces new data showing significant improvement in Psoriasis Area and Severity Index (PASI) scores with ZORYVE cream
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
none
-
News

Arcutis Announces Pricing of $100 Million Public Offering

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announces pricing of public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
offering
-
News

Arcutis Announces Proposed Public Offering

Rhea-AI Summary
Arcutis Biotherapeutics announces underwritten public offering of $100.0 million of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
offering
News

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Rhea-AI Summary
Arcutis Biotherapeutics presents new data on roflumilast foam for the treatment of scalp and body psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Rhea-AI Summary
Arcutis Biotherapeutics expands indication for ZORYVE cream for children with plaque psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
fda approval
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics grants inducement awards to new Chief Commercial Officer and newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
none
News

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

Rhea-AI Summary
Arcutis Biotherapeutics appoints Todd Edwards as Chief Commercial Officer (CCO) and promotes Ayisha Jeter to Senior Vice President, Marketing and Market Access
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
management

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $14.99 as of December 20, 2024.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.8B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.

Stock ARQT logo
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

#2039 Ranked by Market Cap
N/A Ranked by Dividends

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE